{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-387267","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2026-09-10T12:01:18+00:00","discovered_at":"2026-09-10T12:05:00.423924+00:00","generated_at":"2026-09-10T12:05:08.117518+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cerenome secures $21.3M senior secured convertible note facility with 3i Fund","bullets":["Initial closing expected Sept 10, 2026; gross proceeds $3M; total notes $21,276,596 with 6% OID and 8% interest.","Notes convertible at $2.74/share, floor $0.50; maturity one year; secured by first-priority lien on assets and CNSide equity.","Royalty agreement: CNSide pays 2.5% of gross revenues quarterly, capped at 2.5% of outstanding note balance.","Proceeds for working capital; company forecasts cash runway into 2028; additional tranches up to $15.96M available upon milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-387267","json":"https://secwatch.observer/filing/0001193125-26-387267.json","markdown":"https://secwatch.observer/filing/0001193125-26-387267.md","text":"https://secwatch.observer/filing/0001193125-26-387267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526387267/0001193125-26-387267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526387267/d382364d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T12:05:08.117518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}